# Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH

> **NCT02893826** · PHASE1 · TERMINATED · sponsor: **Edge Therapeutics Inc** · enrollment: 6 (actual)

## Conditions studied

- Subarachnoid Hemorrhage, Aneurysmal

## Interventions

- **DRUG:** EG-1962 (nimodipine microparticles)
- **DRUG:** Enteral Nimodipine

## Key facts

- **NCT ID:** NCT02893826
- **Lead sponsor:** Edge Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2017-12
- **Final completion:** 2018-03
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Based on DMC recommendation to discontinue EG-01-1962-03
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02893826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02893826, "Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02893826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*